Skip to main content
. 2018 Dec 14;9(98):37080–37096. doi: 10.18632/oncotarget.26354

Figure 6. Effect of niraparib and olaparib on tumor growth in intracranial BRCA2mut Capan-1-luc or subcutaneous Capan-1 pancreatic cancer xenograft model.

Figure 6

(A) Tumor bioluminescent signals of the intracranial Capan-1-luc model treated with niraparib or olaparib. Niraparib or olaparib was administered at 45 or at 75 mg/kg daily, respectively, for 35 days. Two mice from control group were removed from data analysis since they were identified as the major outliers based on statistical analysis. One mouse from control or niraparib-treated group and two mice from olaparib-treated group died during treatment. (B) Table summarizing TGI and P value calculated by Student’s t test for niraparib or olaparib compared to vehicle on day 36, luc=luciferase; ***P< 0.001, NS=not significant. (C) Tumor growth of the subcutaneous Capan-1 model treated with niraparib or olaparib. Niraparib or olaparib was administered at 45 or at 75 mg/kg daily, respectively, for 44 days. (D) Table summarizing TGI and P value calculated by Student’s t test for niraparib or olaparib compared to vehicle on day 44, ***P< 0.001, *P< 0.05.